OncXerna Therapeutics Announces New Phase 2 and Biomarker Data in Gastric Cancer from Bavituximab Program at the ESMO Congress 2021
22% vs. 4% response rates with bavituximab-pembrolizumab in biomarker positive vs. negative patients using the Xerna™ TME Panel
Excerpt from the Press Release:
WALTHAM, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) — Oncxerna Therapeutics, Inc. (“OncXerna”), a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its targeted oncology therapies, today announced new clinical and biomarker data from its bavituximab program in an electronic poster at the European Society of Medical Oncology (ESMO) Congress 2021.
Data presented in the poster are from ONCG100, an open-label Phase 2 clinical trial evaluating bavituximab, a potentially first-in-class phosphatidylserine (PS) inhibitor designed to reverse immune suppression, in combination with the PD-1 inhibitor pembrolizumab (KEYTRUDA®) in patients with advanced gastric or gastroesophageal junction (GEJ) cancer. Patients participating in the trial were required to undergo pre-treatment biopsies to allow for pre-specified biomarker analysis using the Xerna TME Panel.
“Predictive biomarkers are an urgent need in gastric cancer where treatment options are limited and only a small fraction of patients’ treatment is biomarker driven,” said Dr. Ian Chau, consultant medical oncologist at the Royal Marsden Hospital. “This study used OncXerna’s novel RNA expression-based algorithm to classify the biology of the tumor microenvironment of individual gastric cancer patients and prospectively test the hypothesis that patient tumors classified as having a high immune score by the Xerna TME Panel are more likely to benefit from treatment with bavituximab in combination with pembrolizumab. The results support this hypothesis by showing that the Xerna TME Panel biomarker was predictive of improved treatment response rates. This finding represents a promising new development that warrants further testing.”
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?